A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.

Inclusion Criteria:

• Age range: 18 - 65 years old;

• Meets the revised SLE classification criteria of the American College ofRheumatology in 1997 or the SLE diagnostic classification criteria issued byEULAR/ACR in 2019;

• The SELENA-SLEDAI score is at least 8 points (clinical symptoms are no less than 6points, excluding positive anti-double-stranded DNA (anti-dsDNA) and lowcomplement);

• Has not responded well to hormone and/or immunosuppressant treatment, is intolerantor has recurrence, and is willing to accept tixocortinib/belimumab as a therapeuticdrug.

Exclusion Criteria:

• Any of the following conditions exists: active central nervous system disease,severe active lupus nephritis, HIV infection, hepatitis B or C virus infection, lowgamma globulinemia, liver dysfunction;

• eGFR < 30 mL/min/1.73m², or undergoing hemodialysis or kidney transplantation;

• Pregnant women, or women who are about to become pregnant in the near future, orlactating women;

• Participants who are simultaneously participating in other clinical studies;

• Within 1 year before randomization, received B-cell targeted therapy (includingbelimumab);

• During treatment, used traditional Chinese medicine with immunosuppressive effects (such as Tripterygium wilfordii, White Peony Root, etc.) in combination.